» Articles » PMID: 26861401

Biomimickry of UPEC Cytoinvasion: A Novel Concept for Improved Drug Delivery in UTI

Overview
Journal Pathogens
Date 2016 Feb 11
PMID 26861401
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Urinary tract infections (UTIs) are among the most common bacterial infections. In an increasing number of cases, pathogen (multi-)resistance hampers durable treatment success via the standard therapies. On the functional level, the activity of urinary excreted antibiotics is compromized by the efficient tissue colonization mechanism of uropathogenic Escherichia coli (UPEC). Advanced drug delivery systems aim at exploiting a glycan-mediated targeting mechanism, similar to the UPEC invasion pathway, to increase bioavailability. This may be realized by conjugation of intravesically applied drugs or drug carriers to chosen plant lectins. Higher local drug concentrations in or nearby bacterial reservoirs may be gained, with higher chances for complete eradication. In this study, preliminary parameters to clarify the potential of this biorecognitive approach were evaluated. Glycan-triggered interaction cascades and uptake processes of several plant lectins with distinct carbohydrate specificities were characterized, and wheat germ agglutinin (WGA) could be identified as the most promising targeter for crossing the urothelial membrane barrier. In partially differentiated primary cells, intracellular accumulation sites were largely identical for GlcNAc- and Mannose-specific lectins. This indicates that WGA-mediated delivery may also enter host cells via the FimH-dependent uptake pathway.

Citing Articles

Nanotechnology Involved in Treating Urinary Tract Infections: An Overview.

Crintea A, Carpa R, Mitre A, Petho R, Chelaru V, Nadasan S Nanomaterials (Basel). 2023; 13(3).

PMID: 36770516 PMC: 9919202. DOI: 10.3390/nano13030555.


Plant Lectins: A Review on their Biotechnological Potential Toward Human Pathogens.

Costa A, Malveira E, Mendonca L, Maia M, Silva R, Roma R Curr Protein Pept Sci. 2022; 23(12):851-861.

PMID: 36239726 DOI: 10.2174/1389203724666221014142740.


Hetero-Multivalent Targeted Liposomal Drug Delivery to Treat Infections.

Singla A, Simbassa S, Chirra B, Gairola A, Southerland M, Shah K ACS Appl Mater Interfaces. 2022; 14(36):40724-40737.

PMID: 36018830 PMC: 9480101. DOI: 10.1021/acsami.2c12943.


Trimethoprim-Loaded PLGA Nanoparticles Grafted with WGA as Potential Intravesical Therapy of Urinary Tract Infections-Studies on Adhesion to SV-HUCs Under Varying Time, pH, and Drug-Loading Conditions.

Brauner B, Semmler J, Rauch D, Nokaj M, Haiss P, Schwarz P ACS Omega. 2020; 5(28):17377-17384.

PMID: 32715222 PMC: 7377071. DOI: 10.1021/acsomega.0c01745.

References
1.
van Nieuwkoop C, den Exter P, Elzevier H, den Hartigh J, van Dissel J . Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation. Int J Antimicrob Agents. 2010; 36(6):485-90. DOI: 10.1016/j.ijantimicag.2010.05.005. View

2.
Schilling J, Mulvey M, Hultgren S . Structure and function of Escherichia coli type 1 pili: new insight into the pathogenesis of urinary tract infections. J Infect Dis. 2001; 183 Suppl 1:S36-40. DOI: 10.1086/318855. View

3.
Martinez J, Mulvey M, Schilling J, Pinkner J, Hultgren S . Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J. 2000; 19(12):2803-12. PMC: 203355. DOI: 10.1093/emboj/19.12.2803. View

4.
Foxman B, Barlow R, DArcy H, Gillespie B, Sobel J . Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000; 10(8):509-15. DOI: 10.1016/s1047-2797(00)00072-7. View

5.
Wirth M, Fuchs A, Wolf M, Ertl B, Gabor F . Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells. Pharm Res. 1998; 15(7):1031-7. DOI: 10.1023/a:1011926026653. View